American College of Pediatricians Praises Newly Approved Medicine for Pediatric Type 2 Diabetes

On June 17, 2019, the U.S. Food and Drug Administration approved Victoza (liraglutide) injection for treatment of children 10 years or older with type 2 diabetes. Victoza, which has been approved for use in adults with type 2 diabetes since 2010, is the first non-insulin drug approved to treat type 2 diabetes in children since the release of Metformin in 2000.
Dr. Quentin L. Van Meter, president of the American College of Pediatricians, and a practicing pediatric endocrinologist states, “The general feeling from the pediatric endocrine community on the recent approval of liraglutide for use in children is highly favorable. The existing FDA approved treatments for children with type 2 diabetes are quite limited. The standard approach to treatment is diet and exercise followed by a prescription for Metformin. When this fails, or hyperglycemia is more pronounced at diagnosis, the only other option has been insulin. Some patients do well on basal insulin alone (Lantus or Basaglar) but many will also need short-acting insulin (e.g. Humalog or Novolog). It is a boon to finally have an option beyond Metformin that can be tried before placing our type 2 diabetic patients on insulin.”
The American College of Pediatricians is a national medical association of licensed physicians and healthcare professionals who specialize in the care of infants, children, and adolescents. The mission of the College is to enable all children to reach their optimal, physical and emotional health and well-being.